- Home
- LXRX vs CATX Comparison
LXRX vs CATX Comparison
Compare LXRX & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- CATX
- Stock Information
- Founded
- LXRX 1995
- CATX 1983
- Country
- LXRX United States
- CATX United States
- Employees
- LXRX N/A
- CATX N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- LXRX Health Care
- CATX Health Care
- Exchange
- LXRX Nasdaq
- CATX Nasdaq
- Market Cap
- LXRX 228.8M
- CATX 239.0M
- IPO Year
- LXRX 2000
- CATX N/A
- Fundamental
- Price
- LXRX $0.75
- CATX $3.44
- Analyst Decision
- LXRX Buy
- CATX Strong Buy
- Analyst Count
- LXRX 4
- CATX 10
- Target Price
- LXRX $3.67
- CATX $13.00
- AVG Volume (30 Days)
- LXRX 3.7M
- CATX 1.5M
- Earning Date
- LXRX 07-31-2025
- CATX 08-11-2025
- Dividend Yield
- LXRX N/A
- CATX N/A
- EPS Growth
- LXRX N/A
- CATX N/A
- EPS
- LXRX N/A
- CATX N/A
- Revenue
- LXRX $31,213,000.00
- CATX $1,471,000.00
- Revenue This Year
- LXRX N/A
- CATX N/A
- Revenue Next Year
- LXRX N/A
- CATX N/A
- P/E Ratio
- LXRX N/A
- CATX N/A
- Revenue Growth
- LXRX 1251.21
- CATX N/A
- 52 Week Low
- LXRX $0.28
- CATX $1.60
- 52 Week High
- LXRX $2.45
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- LXRX 61.01
- CATX 60.53
- Support Level
- LXRX $0.64
- CATX $2.96
- Resistance Level
- LXRX $0.77
- CATX $3.77
- Average True Range (ATR)
- LXRX 0.06
- CATX 0.41
- MACD
- LXRX 0.00
- CATX 0.02
- Stochastic Oscillator
- LXRX 76.47
- CATX 73.78
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.